Chronic Heart Failure - Pipeline Insight, 2024

This “Chronic Heart Failure- Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Chronic Heart Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Chronic Heart Failure: Understanding

Chronic Heart Failure: Overview

Chronic heart failure (CHF) is a major public health problem in industrialized societies with an incidence approaching 10 per 1,000 population after age 65 and an age-dependent prevalence of less than 1% between ages 45-55, 2-5% between ages 65-75, and approximately 10% for patients aged 80 years or more. HF is a complex clinical syndrome characterized by the inability of the heart to provide the cardiac output needed by the organism at normal end-diastolic ventricular pressures. Ventricular dysfunction limits exercise tolerance and may impair the quality of life of affected individuals. Clinically, forward failure of the heart leads to low blood pressure and fatigue, while backward failure results in dyspnoe and fluid retention, which may lead to pulmonary congestion, pleural effusions, peripheral edema, as well as impairment of hepatic, gastric, and renal function. Complications of HF include thromboembolic events, arrhythmias, pulmonary edema, cardiogenic shock, and death. Diagnosis of HF is based on history, physical examination, and echocardiography, while additional tests such as 12-lead electrocardiogram, chest radiography, cardiac magnetic resonance imaging, cardiac catheterization, and laboratory testing including brain natriuretic peptide (BNP) levels can provide useful information about the etiology, severity, and prognosis. Chronic heart failure (CHF) is a progressive syndrome that results in a poor quality of life for the patient and places an economic burden on the health care system. Despite advances in the control of cardiovascular diseases such as myocardial infarction (MI), the incidence and prevalence of CHF continue to increase. Regular physical activity (exercising =5 d/wk) and maintaining a healthy body weight are key ingredients to preventing heart failure. Other healthy behaviors also lower the risk of developing heart failure: not smoking, eating fruits and vegetables (4 servings/d), and moderate alcohol intake (1 drink/d). On the other hand, heavy alcohol/binge drinking and cocaine/amphetamine abuse can lead to heart failure and other health problems and thus should be avoided. Lastly, eating fish and drinking a moderate amount of coffee (= 4 cups/d) have also been linked to less heart failure.

“Chronic Heart Failure- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Heart Failure pipeline landscape is provided which includes the disease overview and Chronic Heart Failure treatment guidelines. The assessment part of the report embraces, in depth Chronic Heart Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Heart Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Heart Failure R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Heart Failure.

Chronic Heart Failure Emerging Drugs Chapters

This segment of the Chronic Heart Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chronic Heart Failure Emerging Drugs

Neucardin: Zensun (Shanghai) Sci & Tech Neucardin is a. Recombinant human neuregulin-1 (Neucardin), developed by Zensun, is a novel genetically engineered biologic used in the treatment of mild and moderate chronic heart failure (CHF). The advantage of Neucardin® is that it can specifically target the cardiac muscle cell, repair the cell structure and improve function during heart contraction and relaxation, thereby improving cardiac function and reversing pathological ventricular remodeling, and significantly reducing death rate and readmission rate while improving the quality of life. In August 2019, Zensun USA, Inc., announced that the investigation of NEUCARDIN, its Recombinant human neuregulin-1 fragment, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of Chronic Heart Failure (CHF). NEUCARDIN, the lead drug candidate from the company’s cardiac therapy program, was also recently granted “priority review” for its conditional approval application in China by the National Medical Products Administration (NMPA) (formerly theCFDA).

Omecamtiv Mecarbil: Cytokinetics Omecamtiv mecarbil is an investigational, selective, small molecule cardiac myosin activator, the first of a novel class of myotropes1 designed to directly target the contractile mechanisms of the heart, binding to and recruiting more cardiac myosin heads to interact with actin during systole. Omecamtiv mecarbil is designed to increase the number of active actin-myosin cross bridges during each cardiac cycle and consequently augment the impaired contractility that is associated with heart failure with reduced ejection fraction (HFr EF). Preclinical research has shown that omecamtiv mecarbil increases cardiac contractility without increasing intracellular myocyte calcium concentrations or myocardialoxygenconsumption.

Rexlemestrocel-L (Revascor): Mesoblast Revascor consists of 150 million mesenchymal precursor cells (MPCs) administered by direct injection into the heart muscle in patients suffering from CHF and progressive loss of heart function. MPCs release a range of factors when triggered by specific receptor-ligand interactions within damaged tissue. Based on preclinical data, it is believed that these factors induce functional cardiac recovery by simultaneous activation of multiple pathways, including induction of endogenous vascular network formation, reduction in harmful inflammation, reduction in cardiac scarring and fibrosis, and regeneration of heart muscle through activation of tissue precursors. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Chronic HeartFailure.

Chronic Heart Failure: Therapeutic Assessment

This segment of the report provides insights about the different Chronic Heart Failure drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chronic Heart Failure

There are approx. 25+ key companies which are developing the therapies for Chronic Heart Failure. The companies which have their Chronic Heart Failure drug candidates in the most advanced stage, i.e. Pre-Registration include, Zensun (Shanghai) Sci & Tech.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Chronic Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Heart Failure: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Heart Failure therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Heart Failure drugs.

Chronic Heart Failure Report Insights

• Chronic Heart Failure Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Chronic Heart Failure Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic Heart Failure drugs?
• How many Chronic Heart Failure drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Heart Failure?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Heart Failure therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic Heart Failure and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Zensun (Shanghai) Sci & Tech
• Cytokinetics
• Mesoblast
• Shanghai Hongyitang Biopharmaceutical Technology
• Tasly Pharmaceuticals
• Ionis Pharmaceuticals
• Berlin Cures
• CardioCell
• Help Therapeutics
• Eli Lilly and Company
• Chong Kun Dang Pharmaceutical
• Antlia Biosciences
• Cardiol Therapeutics

Key Products

• Neucardin
• Omecamtiv Mecarbil
• Rexlemestrocel-L (Revascor)
• TSG-01
• Qishenyiqi Dripping Pills
• IONIS-AGT-LRx
• BC-007
• Allogeneic Mesenchymal Bone Marrow Cells
• Hi CM188
• LY3461767
• CKD-349
• Antliabio 110
• CardiolRx

This product will be delivered within 1-3 business days.